Quantum biopharma's 2024 financial statements show strong improvements in cash, working capital, operating efficiency and the removal of material uncertainty related to going concern

Completion of unbuzzd™ clinical trial and multiple sclerosis drug lucid-21-302 phase 1 trial advance company's pipeline of products and assets completion of unbuzzd™ clinical trial and multiple sclerosis drug lucid-21-302 phase 1 trial advance company's pipeline of products and assets
QNTM Ratings Summary
QNTM Quant Ranking